Literature DB >> 26260819

Concomitant tuberculosis and lung cancer diagnosed by bronchoscopy.

C Morales-García1, J Parra-Ruiz2, J A Sánchez-Martínez3, A E Delgado-Martín3, A Amzouz-Amzouz1, J Hernández-Quero2.   

Abstract

SETTING: South Granada Health Area (SGHA), Spain.
OBJECTIVE: To describe the characteristics of concomitant tuberculosis (TB) and lung cancer cases.
DESIGN: A total of 319 TB cases diagnosed between January 2003 and December 2010 were evaluated and identified using a prospective database. During this period, samples of bronchial secretions were obtained from all patients who underwent fibreoptic bronchoscopy (FBS) as part of a TB screening programme. A descriptive study was conducted.
RESULTS: Concomitant TB and lung cancer were diagnosed in 15 cases (4.7% of total TB cases). The most common radiographic finding was atelectasis (53.3%), and the most common histological type was epidermoid carcinoma (60%). Lung cancer stage was advanced (III-IV) in 60% of the cases.
CONCLUSION: The association between TB and lung cancer found in the SGHA after implementing a TB screening programme was higher than in other studies. This suggests that it would be advisable to perform acid-fast bacilli smear and mycobacterial culture of bronchial aspirates in all patients with presumed lung cancer, particularly in high TB prevalence areas.

Entities:  

Mesh:

Year:  2015        PMID: 26260819     DOI: 10.5588/ijtld.14.0578

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Incidental diagnosis of pulmonary mycobacteriosis among patients scheduled for lung cancer surgery: results from a series of 3224 consecutive operations.

Authors:  Francesco Petrella; Monica Casiraghi; Elena Prisciandaro; Lorenzo Gherzi; Lorenzo Spaggiari
Journal:  Heliyon       Date:  2019-03-27

2.  Oncocytic carcinoid tumor of the lung complicated by tuberculosis.

Authors:  Jie-Min Zhao; Yang Li; Ying Tang; Xiao-Bo Ma; Xin Zhao
Journal:  Chin Med J (Engl)       Date:  2019-08-05       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.